Edwards Lifesciences Corp reports $1.65 billion revenue for quarter ended March 31, 2026

ยท EW

Edwards Lifesciences Corp reported revenue of $1.65 billion for the quarter ended March 31, 2026.

For the same period it posted net income of $380.7 million, or $0.66 per diluted share.

That is a net margin of 23.1%.

On Sanad's AAOIFI Standard 21 screen, Edwards Lifesciences Corp is currently compliant: interest-bearing debt is 1% of market capitalisation (limit 30%), and impure income is 2.8% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on May 6, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Edwards Lifesciences Corp news